Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: Global - Vaccine Market (Billion US$), 2012-2017
Figure 4-1: Global - Causes of Deaths in Children (<5 Years) among Low-income Countries (%), 2011
Figure 4-2: Global - Pneumococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-3: Global - Influenza Vaccine Market (Billion US$), 2012-2017
Figure 4-4: Global - Cancer Vaccine Market (Billion US$), 2012-2017
Figure 4-5: Global - Polio Vaccine Market (Billion US$), 2012-2017
Figure 4-6: Global - Varicella Vaccine Market (Billion US$), 2012-2017
Figure 4-7: Global - Rotavirus Vaccine Market (Billion US$), 2012-2017
Figure 4-8: Global - Meningococcal Vaccine Market (Billion US$), 2012-2017
Figure 4-9: Global - Number of Diphtheria Incidences by Region (2009 & 2010)
Figure 4-10: Global - Number of Ntetanus Incidences by Region (2009 & 2010)
Figure 4-11: Global - Number of Ttetanus Incidences by Region (2009 & 2010)
Figure 4-12: Global - Number of Pertussis Incidences by Region (2009 & 2010)
Figure 4-13: Global - DTP Vaccine Market (Billion US$), 2012-2017
Figure 4-14: Global - Hepatitis Vaccine Market (Million US$), 2012-2017
Figure 4-15: Global - Number of Measles Incidences by Region (2009 & 2010)
Figure 4-16: Global - Number of Mumps Incidences by Region (‘000), 2009 & 2010
Figure 4-17: Global - Number of Rubella Incidences by Region (2009 & 2010)
Figure 4-18: Global - MMR Vaccine Market (Million US$), 2012-2017
Figure 4-19: Global - Japanese Encephalitis Market (Million US$), 2012-2017
Figure 4-20: Global - Sources for Funding in HIV Vaccine R&D (%), 2011
Figure 5-1: Global - Vaccine Market by Region (%), 2012
Figure 5-2: Global - Vaccine Market by Region (%), 2017
Figure 5-3: US - Vaccine Market (Billion US$), 2012-2017
Figure 5-4: Europe - Vaccine Market (Billion US$), 2012-2017
Figure 5-5: Japan - Vaccine Market (Billion US$), 2012-2017
Figure 5-6: China - Vaccine Market (Billion US$), 2012-2017
Figure 5-7: India - Share of Domestic Consumption and Exports in Vaccine Market (2010)
Figure 5-8: India - Vaccine Market (Billion US$), 2012-2017
Figure 5-9: Brazil - Vaccine Market (Billion US$), 2012-2017
Figure 6-1: Global - Share of Key Players in Vaccine Market (2012)
Figure 6-2: GSK - Revenue Breakup by Business Segment (%), 2012
Figure 6-3: GSK - Vaccine Revenue Breakup by Product (%), 2012
Figure 6-4: Sanofi-Pasteur - Revenue Breakup by Business Segment (%), 2012
Figure 6-5: Sanofi-Pasteur - Vaccine Revenue Breakup by Product (%), 2012
Figure 6-6: Pfizer - Revenue Breakup by Business Segment (%), 2012
Figure 6-7: Pfizer - Revenue Breakup by Biopharmaceuticals (%), 2012
Figure 6-8: Merck - Revenue Breakup by Business Segment (%), 2012
Figure 6-9: Merck - Pharmaceutical Division Revenue by Segment (%), 2012
Figure 6-10: Novartis - Revenue Breakup by Business Segment (%), 2012
Figure 6-11: AstraZeneca - Revenue Breakup by Therapy Area (%), 2012
Figure 6-12: Baxter International - Revenue Breakup by Business Segment (%), 2012
Figure 6-13: BioCSL - Revenue Breakup by Business Segment (%), 2012
Figure 6-14: Takeda Pharmaceutical - Revenue Breakup by Business Segment (%), 2012
Figure 6-15: Crucell - Revenue Breakup by Vaccine Type (%), 2010
 
List of Tables:

Table 4-1: Pneumococcal Vaccine Market - Key Players and Vaccines
Table 4-2: Key Pneumococcal Vaccines in Pipeline
Table 4-3: Influenza Vaccine Market - Key Players and Vaccines
Table 4-4: Key Influenza Vaccines in Pipeline
Table 4-5: Global - Cancer Statistics in More Developed and Less Developed Regions (2008)
Table 4-6: Cancer Vaccine Market - Key Players and Vaccines
Table 4-7: Key Cancer Vaccines in Pipeline
Table 4-8: Polio Vaccine Market - Key Players and Vaccines
Table 4-9: Key Polio Vaccines in Pipeline
Table 4-10: Varicella Vaccine Market - Key Players and Vaccines
Table 4-11: Rotavirus Vaccine Market - Key Players and Vaccines
Table 4-12: Key Rotavirus Vaccines in Pipeline
Table 4-13: Meningococcal Vaccine Market - Key Players and Vaccines
Table 4-14: Key Meningococcal Vaccines in Pipeline
Table 4-15: DTP Vaccine Market - Key Players and Vaccines
Table 4-16: Key DTP Vaccines in Pipeline
Table 4-17: Hepatitis Vaccine Market - Key Players and Vaccines
Table 4-18: Key Hepatitis Vaccines in Pipeline
Table 4-19: MMR Vaccine Market - Key Players and Vaccines
Table 4-20: Key MMR Vaccines in Pipeline
Table 4-21: Japanese Encephalitis Vaccine Market - Key Players and Vaccines
Table 4-22: Key Japanese Encephalitis Vaccines in Pipeline
Table 4-23: Tuberculosis Vaccine Market - Key Players and Vaccines
Table 4-24: Key Tuberculosis Vaccines in Pipeline
Table 4-25: Key Malaria Vaccines in Pipeline
Table 4-26: Rabies Vaccine Market - Key Players and Vaccines
Table 4-27: Key Rabies Vaccines in Pipeline
Table 4-28: Typhoid Vaccine Market - Key Players and Vaccines
Table 4-29: Key Typhoid Vaccines in Pipeline
Table 4-30: Global - Number of HIV/AIDS Patients by Region (2009)
Table 4-31: Key HIV Vaccines in Pipeline
Table 5-1: China - Vaccine Classification
Table 5-2: China - Annual Pediatric Vaccine Doses Requirement (Million Doses)
Table 6-1: GSK - Vaccines Portfolio
Table 6-2: GSK - Vaccines in Pipeline
Table 6-3: GSK - Strengths and Weaknesses
Table 6-4: Sanofi-Pasteur - Vaccines Portfolio
Table 6-5: Sanofi-Pasteur - Vaccines in Pipeline
Table 6-6: Sanofi-Pasteur - Strengths and Weaknesses
Table 6-7: Pfizer - Vaccines Portfolio
Table 6-8: Pfizer - Vaccines in Pipeline
Table 6-9: Pfizer - Strengths and Weaknesses
Table 6-10: Merck - Vaccines Portfolio
Table 6-11: Merck - Vaccines in Pipeline
Table 6-12: Merck - Strengths and Weaknesses
Table 6-13: Novartis - Vaccines Portfolio
Table 6-14: Novartis - Vaccines in Pipeline
Table 6-15: Novartis - Strengths and Weaknesses
Table 6-16: Emergent Biosolutions - Vaccines Portfolio
Table 6-17: Emergent Biosolutions - Vaccines in Pipeline
Table 6-18: Emergent Biosolutions - Strengths and Weaknesses
Table 6-19: AstraZeneca - Vaccines Portfolio
Table 6-20: AstraZeneca - Vaccines in Pipeline
Table 6-21: AstraZeneca - Strengths and Weaknesses
Table 6-22: Baxter International - Vaccines Portfolio
Table 6-23: Baxter International - Vaccines in Pipeline
Table 6-24: Baxter International - Strengths and Weaknesses
Table 6-25: BioCSL - Vaccines Portfolio
Table 6-26: BioCSL - Strengths and Weaknesses
Table 6-27: Dendreon Corporation - Vaccines Portfolio
Table 6-28: Dendreon Corporation - Vaccines in Pipeline
Table 6-29: Dendreon Corporation - Strengths and Weaknesses
Table 6-30: Takeda Pharmaceutical - Vaccines Portfolio
Table 6-31: Takeda Pharmaceutical - Vaccines in Pipeline
Table 6-32: Takeda Pharmaceutical - Strengths and Weaknesses
Table 6-33: Crucell - Vaccines Portfolio
Table 6-34: Crucell - Vaccines in Pipeline
Table 6-35: Crucell - Strengths and Weaknesses